一种防治绿脓杆菌感染的制剂——抗绿脓杆菌超免疫血浆,国内首次由上海市中心血站、上海第二医学院附属瑞金医院和黑龙江省应用微生物研究所初步研制成功,目前治疗13例病人效果显著。绿脓杆菌不仅感染率高,而且耐药性强(耐药菌株达30～50％,广谱耐药)。据文献记载,烧伤死亡病例中约有80％伴有此菌感染,感染后发生败血症者死亡率达60％以上。七十年代中叶有关绿脓杆菌 A preparation for prevention and treatment of Pseudomonas aeruginosa infection - anti-Pseudomonas aeruginosa hyperimmune plasma, for the first time by the Shanghai Blood Center, Shanghai Second Medical College Ruijin Hospital and Heilongjiang Province Institute of Applied Microbiology preliminary research and development, the current treatment of 13 Cases of patients with remarkable results. Pseudomonas aeruginosa infection rate is not only high, but also resistant (resistant strains of up to 30 to 50%, broad-spectrum resistance). According to the literature, about 80% of burn deaths are associated with this bacterial infection, and the mortality rate of sepsis after infection is over 60%. The mid-seventies about Pseudomonas aeruginosa